Influenza pandemics are caused by viruses that possess an Hemagglutinin molecule to which most of the population lacks immunity. If such virus is pathogenic to human and demonstrates the ability to transmit from person to person, the result is a global outbreak of disease that affects a high percentage of individuals in a short period of time and is likely to cause substantially increased mortality and morbidity in all countries of the world. Recently, purely avian influenza viruses, including the H5N1, H9N2 and H7N7 subtypes, have been directly transmitted to humans, raising concern over the possibility of a new influenza pandemic among the world's immunologically naive populations. In order to face this kind of situation, a pandemic influenza vaccine has to be developed.
Age range
60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 10 post Dose 1
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 1
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 10 post Dose 1
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 1
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 10 post Dose 1
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 1
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 10 post Dose 1
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 1
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 10 post Dose 1
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 1
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 2 (Day 42)
Serum HI Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2)
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Seroconverted Subjects Against Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Seroconversion Factor for Influenza A Subtype H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Seroprotected Subjects Against H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 2 (Day 42)
Number of Subjects With Seroprotection Power Against H9N2
Timeframe: At Day 21 post Dose 3 (Day 210 for Subset 1 groups and Day 386 for Subset 2 groups)